AIF1L

Across TCGA pan-cancer cohorts, AIF1L mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of AIF1L’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where AIF1L mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AIF1L is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where AIF1L tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AIF1L mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	IV	−1.997	<.001	12	view →
HNSC	All	IV	−1.861	<.001	11	view →
LSCC	Female	All	−1.267	<.001	8	view →
LUAD	Male	III,IV	−1.116	<.001	8	view →
PDAC	Male	All	−0.794	<.001	8	view →
COAD	All	All	−1.136	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

AIF1L–CCRCC

Open the CCRCC breakdown →